New SGS biopharmaceutical testing capabilities in Illinois

SGS Lincolnshire.

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

The investment, both in expertise and equipment, will extend the biopharmaceutical testing services offered by SGS’s current US and Canadian Life Science facilities. Using state-of-the-art methodologies and instrumentation, the new services will focus on quality control analysis and stability testing of biopharmaceuticals.

The site currently offers a wide range of analytical services, and has adapted 313 m3 of stability storage to meet the lower temperature regulatory requirements for peptides and proteins. This additional investment will allow SGS to offer greater capacity for GMP biologics testing capabilities in North America to better serve its biopharmaceutical clients.

“Because of its strategic geographic location, in what is a rich cluster of biopharmaceutical companies, strengthening the capabilities at the Lincolnshire laboratory will allow SGS to act as a local partner for innovators looking for expertise in biopharmaceutical analysis,” said James Nokes, Vice President of US Agriculture, Food and Life at SGS. “SGS maintains its commitment to invest in its network of laboratories to offer integrated solutions, and evolve for both the local and global needs of its clients.”

This new development is part of a wider program of investments in the company’s global laboratory network. In August 2017, SGS announced a 50% expansion of its Lincolnshire laboratory, growing its footprint to nearly 58,000 sq. ft. Increases in extractables and leachables capabilities have also taken place at Fairfield, New Jersey, and Shanghai, China; while French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis respectively.